key: cord-0861265-fhu5blfr
authors: Margolin, Emmanuel; Verbeek, Matthew; Meyers, Ann; Chapman, Ros; Williamson, Anna-Lise; Rybicki, Edward P
title: Calreticulin co-expression supports high level production of a recombinant SARS-CoV-2 spike mimetic in Nicotiana benthamiana
date: 2020-06-14
journal: bioRxiv
DOI: 10.1101/2020.06.14.150458
sha: aa9d9112e10130bc9f8886d6297cae6dad5a0ed5
doc_id: 861265
cord_uid: fhu5blfr

An effective prophylactic vaccine is urgently needed to protect against SARS-CoV-2 infection. The viral spike, which mediates entry into cells by interacting with the host angiotensin-converting enzyme 2, is the primary target of most vaccines in development. These vaccines aim to elicit protective immunity against the glycoprotein by use of inactivated virus, vector-mediated delivery of the antigen in vivo, or by direct immunization with the purified antigen following expression in a heterologous system. These approaches are mostly dependent on the growth of mammalian or insect cells, which requires a sophisticated infrastructure that is not generally available in developing countries due to the incumbent costs which are prohibitive. Plant-based subunit vaccine production has long been considered as a cheaper alternative, although low expression yields and differences along the secretory pathway to mammalian cells have posed a challenge to producing certain viral glycoproteins. Recent advances that have enabled many of these constraints to be addressed include expressing the requisite human proteins in plants to support the maturation of the protein of interest. In this study we investigated these approaches to support the production of a soluble and putatively trimeric SARS-CoV-2 spike mimetic in Nicotiana benthamiana via transient Agrobacterium-mediated expression. The co-expression of human calreticulin dramatically improved the accumulation of the viral spike, which was barely detectable in the absence of the co-expressed accessory protein. The viral antigen was efficiently processed even in the absence of co-expressed furin, suggesting that processing may have occurred at the secondary cleavage site and was mediated by an endogenous plant protease. In contrast, the spike was not efficiently processed when expressed in mammalian cells as a control, although the co-expression of furin improved processing considerably. This study demonstrates the feasibility of molecular engineering to improve the production of viral glycoproteins in plants, and supports plant-based production of SARS-CoV-2 spike-based vaccines and reagents for serological assays.

sophisticated infrastructure that is not generally available in developing countries due to the 23 incumbent costs which are prohibitive. Plant-based subunit vaccine production has long been 24 considered as a cheaper alternative, although low expression yields and differences along the 25 secretory pathway to mammalian cells have posed a challenge to producing certain viral 26 glycoproteins. Recent advances that have enabled many of these constraints to be addressed 27 include expressing the requisite human proteins in plants to support the maturation of the 28 protein of interest. In this study we investigated these approaches to support the production of 29 a soluble and putatively trimeric SARS-CoV-2 spike mimetic in Nicotiana benthamiana via 30 transient Agrobacterium-mediated expression. The co-expression of human calreticulin 31 dramatically improved the accumulation of the viral spike, which was barely detectable in the 32 absence of the co-expressed accessory protein. The viral antigen was efficiently processed 33 even in the absence of co-expressed furin, suggesting that processing may have occurred at 34 the secondary cleavage site and was mediated by an endogenous plant protease. In contrast, 35 the spike was not efficiently processed when expressed in mammalian cells as a control, 36 although the co-expression of furin improved processing considerably. This study 37 demonstrates the feasibility of molecular engineering to improve the production of viral 38 glycoproteins in plants, and supports plant-based production of SARS-CoV-2 spike-based 39 vaccines and reagents for serological assays. production was therefore proposed as an alternative platform for vaccine development, due to 53 the potential for rapid large scale antigen production [3]. The system is also well-suited to 54 developing countries where financial resources are often lacking, as the costs to establish a 55 manufacturing facility and to produce pharmaceuticals are lower than those required for 56 conventional mammalian cell production platforms [4] . Accordingly, several candidate Many other viral glycoproteins, however, do not accumulate at such high levels in plants and 63 the host cellular machinery may not adequately support critical folding and processing events 64 that are required for glycoprotein maturation [3] . Furin, the enzyme responsible for the 65 proteolytic processing of many viral glycoproteins, is not naturally produced in plants [10] . 66 Additional constraints, such as the host chaperone machinery or differences in the plant 67 oligosaccaryltransferase complex, may also complicate the production of, and glycosylation 68 of, certain viral glycoproteins in planta [11] [12] [13] . Recently, it has been proposed that 69 engineering the plant secretory pathway to support the production of viral glycoproteins 

Setting up a platform for plant-based influenza virus vaccine production 220 in South Africa

COVID-19 vaccine development pipeline gears up

Production of complex viral glycoproteins in plants as vaccine 224 immunogens

Molecular Pharming for low and middle income countries

Safety and immunogenicity of a plant-produced recombinant 228 monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 229 virus: a Phase 1 dose-escalation study in healthy adults

A plant-derived quadrivalent virus like particle influenza vaccine induces 231 cross-reactive antibody and T cell response in healthy adults

Immunogenicity and safety of a quadrivalent plant-derived virus like particle 234 influenza vaccine candidate-Two randomized Phase II clinical trials in 18 to 49 and >/=50 235 years old adults

Influenza virus-like particles produced by transient expression in 237

Nicotiana benthamiana induce a protective immune response against a lethal viral challenge 238 in mice

Engineering the Plant Secretory Pathway for the Production of Next-240 Generation Pharmaceuticals

Co-expression of the protease furin in Nicotiana benthamiana leads to 242 efficient processing of latent transforming growth factor-beta1 into a biologically active 243 protein

Efficient N-Glycosylation of the Heavy Chain Tailpiece Promotes the 245 Formation of Plant-Produced Dimeric IgA. Frontiers in Chemistry

An oligosaccharyltransferase from Leishmania major increases the N-247 glycan occupancy on recombinant glycoproteins produced in Nicotiana benthamiana. Plant 248

Co-expression of human calreticulin significantly improves the production 250 of HIV gp140 and other viral glycoproteins in plants

SARS-CoV-2 Vaccines: Status Report. Immunity

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by 253 a Clinically Proven Protease Inhibitor

Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex 255 with its host cell receptor ACE2

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. 257 Cell

Enhancing the proteolytic maturation of human immunodeficiency virus 259 type 1 envelope glycoproteins

Production and Immunogenicity of Soluble Plant-Produced HIV-1 Subtype 261 C Envelope gp140 Immunogens

Optimization of human papillomavirus type 16 (HPV-16) L1 expression in 263 plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-264 compartment localization

pEAQ: versatile expression vectors 266 for easy and quick transient expression of heterologous proteins in plants

The porcine circovirus type 1 capsid gene promoter improves antigen 269 expression and immunogenicity in a HIV-1 plasmid vaccine